Search Results - "Smyth, Elizabeth C"

Ramucirumab: successfully targeting angiogenesis in gastric cancer by Javle, Milind, Smyth, Elizabeth C, Chau, Ian

“…Gastric cancer is the fourth most common cancer globally and represents the second most common cause of cancer-related mortality. Early detection, aggressive…”
Get full text

Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial by Cunningham, David, Prof, Stenning, Sally P, Prof, Smyth, Elizabeth C, MBBCh, Okines, Alicia F, MD, Allum, William H, MD, Rowley, Sam, MSc, Stevenson, Laura, MSc, Grabsch, Heike I, Prof, Alderson, Derek, Prof, Crosby, Thomas, FRCR, Griffin, S Michael, Prof, Mansoor, Wasat, PhD, Coxon, Fareeda Y, MBBS, Falk, Stephen J, MD, Darby, Suzanne, MBChB, Sumpter, Kate A, MD, Blazeby, Jane M, Prof, Langley, Ruth E, Prof

“…Summary Background Peri-operative chemotherapy and surgery is a standard of care for patients with resectable oesophagogastric adenocarcinoma. Bevacizumab, a…”
Get full text

Late-line treatment in metastatic gastric cancer: today and tomorrow by Smyth, Elizabeth C., Moehler, Markus

“…Survival for patients with unresectable advanced or recurrent gastric cancer (GC) remains poor and the historical lack of evidence-based therapeutic options…”
Get full text

Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction by Davies, Andrew R, Gossage, James A, Zylstra, Janine, Mattsson, Fredrik, Lagergren, Jesper, Maisey, Nick, Smyth, Elizabeth C, Cunningham, David, Allum, William H, Mason, Robert C

“…Neoadjuvant chemotherapy is established in the management of most resectable esophageal and esophagogastric junction adenocarcinomas. However, assessing the…”
Get full text

Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancer by Chénard-Poirier, Maxime, Smyth, Elizabeth C.

“…Immune checkpoint blockade has revolutionised the treatment of multiple cancers including melanoma, non-small cell lung cancer, urothelial and renal cell…”
Get full text

Encouraging results for PD-1 inhibition in gastric cancer by Smyth, Elizabeth C, Cunningham, David

“…[...]it is unclear whether the radiological responses that have been reported in seemingly PD-L1-negative patients treated with anti-PD1 therapies in…”
Get full text

Novel targets in the treatment of advanced gastric cancer: a perspective review by Fontana, Elisa, Smyth, Elizabeth C.

“…Gastric cancer is responsible for a high burden of disease globally. Although more extensive use of chemotherapy together with the recent introduction of the…”
Get full text

Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers by Sundar, Raghav, Smyth, Elizabeth C., Peng, Siyu, Yeong, Joe P. S., Tan, Patrick

“…Immune checkpoint inhibition has transformed cancer treatment. For gastroesophageal cancer, this class of drugs have demonstrated durable responses and…”
Get full text

Biomarkers for Precision Treatment in Gastric Cancer by Petrillo, Angelica, Smyth, Elizabeth C.

“…Background: Gastric cancer (GC) is one of the most lethal cancers worldwide. Although GC was historically considered a single entity within the organ of…”
Get full text

Reply to: Letter to editor on the article “Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy” by Yeong, Joe, Teo, Chong Boon, Tay, Ryan Yong Kiat, Tan, Benjamin Kye Jyn, Chan, Yiong Huak, Smyth, Elizabeth C., Sundar, Raghav

Get full text

Addition of nivolumab to chemotherapy in patients with advanced gastric cancer: a relevant step ahead, but still many questions to answer by Smyth, Elizabeth C, Cervantes, Andrés

Get full text

Adjuvant or neoadjuvant therapy for operable esophagogastric cancer? by Moorcraft, Sing Yu, Smyth, Elizabeth C., Cunningham, David

“…Esophagogastric cancer encompasses proximal squamous cell carcinoma of the esophagus, distal esophageal/junctional adenocarcinoma of the esophagus and gastric…”
Get full text

Emerging targets in gastroesophageal adenocarcinoma: what the future looks like by Petrillo, Angelica, Smyth, Elizabeth C., van Laarhoven, Hanneke W. M.

“…Gastroesophageal adenocarcinoma (GEA) is a heterogeneous disease with a poor prognosis. Chemotherapy has been the cornerstone in treating metastatic diseases…”
Get full text

Combination immune checkpoint inhibition for older patients with oesophageal squamous cell cancer by Baker, Harriet C, Smyth, Elizabeth C

Get full text

Emerging molecular targets and therapy for cholangiocarcinoma by Kayhanian, Hamzeh, Smyth, Elizabeth C, Braconi, Chiara

“…Cholangiocarcinoma(CCA) is a rare cancer arising from the biliary tree with a poor prognosis and limited therapeutic options. Recent large scale molecular…”
Get full text

Extension of the European Medicines Agency (EMA) approval of trifluridine/tipiracil for gastric cancer by Alsina, Maria, Smyth, Elizabeth C

Get full text

Gastric cancer by Smyth, Elizabeth C, Nilsson, Magnus, Grabsch, Heike I, van Grieken, Nicole CT, Lordick, Florian

“…Gastric cancer is the fifth most common cancer and the third most common cause of cancer death globally. Risk factors for the condition include Helicobacter…”
Get full text

Combining chemotherapy, trastuzumab, and immune-checkpoint inhibitors in HER2-positive gastro-oesophageal cancer by Smyth, Elizabeth C, Sundar, Raghav

“…In an earlier interim analysis of the study (n=434), a difference in radiological response rates (74·4% vs 51·9%) was sufficient to achieve interim regulatory…”
Get full text

Chemotherapy for resectable microsatellite instability-high gastric cancer? by Smyth, Elizabeth C

“…[...]as expected with an immunogenic, high neoantigen expressing tumour, the 8–10% of patients who are diagnosed with operable MSI tumours have excellent…”
Get full text

Improved survival in resected oesophageal and gastric adenocarcinomas over a decade: the Royal Marsden experience 2001–2010 by Fontana, Elisa, Smyth, Elizabeth C., Cunningham, David, Rao, Sheela, Watkins, David, Allum, William H., Thompson, Jeremy, Waddell, Tom, Peckitt, Clare, Chau, Ian, Starling, Naureen

“…Background Oesophageal and gastric adenocarcinoma (OGA) treatment remains challenging. Improvements in early diagnosis, staging and management might have…”
Get full text